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Abstract In baboon smooth muscle cells (SMCs), pervanadate
has a biphasic dose-dependent effect on MEK-1 activity. After a
30 min incubation period, low concentrations (1^10 WM)
activate, while higher doses (30^100 WM) fail to stimulate
MEK-1. One possibility is that higher doses of pervanadate
induce an additional signaling pathway that inhibits MEK-1.
Three lines of investigations provide support for the conclusion
that this inhibitory effect is mediated by p38MAPK. First,
pervanadate induces p38MAPK activity at concentrations that fail
to activate MEK-1. Second, pervanadate-stimulated p38MAPK
activity is maximal after a 10 min incubation, at a time, when
MEK-1 activity disappears. Third, addition of the specific
p38MAPK inhibitor SB203580 preserves MEK-1 activation by
100 WM pervanadate. The inhibitory effect of p38MAPK is
probably not due to a phosphorylation of MEK-1 although we
can not rule out that other p38MAPK isoforms such as SAPK3
and SAPK4 may be involved, and may directly phosphorylate
and inhibit MEK-1.
z 1998 Federation of European Biochemical Societies.
Key words: Signal transduction; Smooth muscle;
Oxidative stress; SB203580
1. Introduction
Time-dependent activation of mitogen-activated protein
kinases (MAPKs) is integral to many signal transduction
pathways (reviewed in [1]). Members of this subfamily of pro-
tein kinases include the extracellular signal-regulated kinases
(ERK-1 and -2) which are involved in proliferation and di¡er-
entiation, and the stress-activated protein kinases (SAPKs)
which mediate cellular stress signaling. SAPKs consist of at
least two subfamilies, the jun kinases and p38MAPK (reviewed
in [1,2]). MAPKs are activated by speci¢c upstream kinases
(MAPK kinases or MEKs) which phosphorylate both threo-
nine and tyrosine residues in a conserved TXY motif in kinase
subdomain VIII (reviewed in [3]). Growth factor-induced ac-
tivation of ERK-1 and -2 is a crucial event for both cell cycle
progression and survival. In contrast, SAPKs are activated by
stress factors, such as reactive oxygen species or UV light,
which inhibit proliferation. In some cell types, SAPKs also
play an active role in apoptotic pathways [4^7]. Although
direct cross talk between di¡erent MAPK pathways has
been suggested [8,9] a direct interaction has not yet been iden-
ti¢ed. This study demonstrates that pervanadate-induced
p38MAPK activity has an inhibitory e¡ect on the ERK-1, -2
activator MEK-1 in aortic baboon smooth muscle cells.
2. Materials and methods
2.1. Materials
Antibodies against MEK-1 were purchased from Transduction
Laboratories (Lexington, KY). Antibodies against p38MAPK and
Raf-1 were from Santa Cruz Biotechnology (Santa Cruz, CA). MAP-
KAPK-2 substrate peptide and antibodies were from Upstate Biotech-
nology (Lake Placid, NY). Protein A agarose was from Sigma (St.
Louis, MO), tissue culture media and fetal calf serum were from
GIBCO-BRL (Gaithersburg, MD). SB203580 was from Calbiochem
(La Jolla, CA) and 32P-Q-ATP from Du Pont-New England Nuclear
(Boston, MA). Catalytically inactive, histidine-tagged mutants of
ERK-2 (K52R), and MEK-1 (K97M) were prepared with minor mod-
i¢cations as described [10,11]. Puri¢ed GST-ATF-2 was a kind gift
from Jonathan Graves (Department of Pharmacology, University of
Washington, Seattle, WA). A stock solution of 50 mM pervanadate
was freshly prepared by mixing equal volumes of 0.1 M Na-ortho-
vanadate and 0.1 M hydrogen peroxide.
Bu¡er HEB: 25 mM HEPES-NaOH, pH 7.5, 10% glycerol, 5 mM
EDTA, 5 mM EGTA, 150 mM NaCl, 100 mM Na-pyrophosphate,
50 mM NaF, 1 mM Na-vanadate, 1 mM benzamidine, 0.1% 2-mer-
captoethanol, 1% Triton X-100, 1 WM pepstatin A, 2 Wg/ml leupeptin
and 20 kallikrein inhibitor units/ml aprotinin; kinase bu¡er: 20 mM
HEPES-NaOH, pH 7.5, 20 mM MgCl2, 0.1% 2-mercaptoethanol;
TTBS bu¡er: 25 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.1% Triton
X-100, 0.1% 2-mercaptoethanol.
2.2. Cell culture
Baboon aortic smooth muscle cells were prepared as described pre-
viously [12]. Cells in passage numbers ranging between 5 and 25 were
grown in Dulbecco’s modi¢ed Eagle’s medium supplemented with
10% FCS, 200 U/ml penicillin and 0.2 mg/ml streptomycin.
2.3. Kinase assays
Subcon£uent (V70%) SMCs were starved for 2^3 days in serum-
free media before stimulation as indicated in the text. Cells were
harvested and extracted in bu¡er HEB as described [13]. One Wg of
antibody and 20 Wl of protein A sepharose slurry (1 mg/ml protein A)
were added to 0.25^0.5 mg extracted protein, depending on the experi-
ment. The samples were stirred overnight at 4‡C. The beads were
washed once in bu¡er HEB followed by TTBS and kinase bu¡er.
The kinase reaction was performed on the beads in kinase bu¡er
containing 1 Wg of protein substrate (or 0.2 mM substrate peptide
in MAPKAPK-2 assays), and 0.1 mM ATP (5000 cpm/pmol). The
assay mix was incubated for 30^45 min at room temperature. For
MEK-1, p38MAPK, and Raf-1 assays, the reactions were terminated
by adding 10 Wl 4ULaemmli bu¡er and the samples were subjected to
SDS-PAGE [14]. The gels were stained with Coomassie-blue to mon-
itor equal loading, dried, and the extent of substrate phosphorylation
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was determined by phosphorimaging (facility at the University of
Washington, Seattle, WA) or densitometric analysis of the autoradio-
graph. Assays were performed in duplicates. The MAPKAPK-2 sam-
ples were spun and the supernatant spotted on P81 paper (Whatman
Inc., Clifton, NJ). Following ¢ve washes with 0.75% phosphoric acid,
the paper-bound radioactivity was determined by scintillation count-
ing.
3. Results and discussion
3.1. Pervanadate has a biphasic e¡ect on MEK activity
Pervanadate, a mixture of vanadate and hydrogen peroxide,
is widely used as potent phosphatase inhibitor [15,16] and has
recently been shown to strongly activate the ERK/MEK sig-
naling module in HeLa cells [17]. Surprisingly, a biphasic
dose-dependent e¡ect of pervanadate on MEK-1 activation
was observed in smooth muscle cells (SMCs) following a
30 min incubation period. Concentrations of pervanadate up
to 10 WM activated MEK-1, whereas concentrations greater
than 10 WM did not (Fig. 1A, B). Time course experiments
with 10 and 100 WM pervanadate revealed that 100 WM per-
vanadate was capable of activating MEK-1 at 10 min, but
kinase activity was short-lived and completely disappeared
after 30 min (Fig. 1C). In contrast, MEK-1 activity induced
by 10 WM pervanadate peaked at 30 min and remained above
basal levels after 1 h (Fig. 1C). One explanation for these
kinetic di¡erences may lie in the possibility that pervanadate
in concentrations higher than 10 WM initiates an additional
signaling pathway that can inhibit MEK-1. It is noteworthy
that vanadate, but not peroxide, activated MEK-1 to a similar
extent when compared to pervanadate. Vanadate, however,
completely lacked any inhibitory e¡ect at higher concentra-
tions. These ¢ndings suggest that the e¡ects of pervanadate on
MEK-1 may require both the activatory action of vanadate
and an inhibitory action of peroxide.
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Fig. 1. E¡ects of pervanadate on MEK-1. MEK-1 activities were
determined with recombinant ERK-2 as substrate in extracts from
SMCs that have been stimulated with pervanadate. A, B: SMCs
were incubated for 30 min with 1, 3, 10, 30, and 100 WM pervana-
date, respectively. A: Autoradiograph of a representative experi-
ment. B: Graph representing mean values of 2^3 independent ex-
periments. C: SMCs were incubated with 10 WM (open circles) and
100 WM (solid circles) pervanadate for 10, 30, and 60 min respec-
tively. Mean values of 2^3 independent experiments are shown.
Fig. 2. E¡ects of pervanadate on p38MAPK. p38MAPK activities were
determined with GST-ATF-2 as substrate in extracts from SMCs
that have been stimulated with pervanadate. A, B: SMCs were incu-
bated for 10 min with 1, 3, 10, 30, and 100 WM pervanadate, re-
spectively. A: Autoradiograph of a representative experiment.
B: Graph representing mean values of 2^3 independent experiments.
C: SMCs were incubated with 100 WM pervanadate for 10, 30, and
80 min respectively. Mean values of two independent experiments
are shown.
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3.2. MEK-1 inhibition by pervanadate is mediated by p38MAPK
As p38MAPK is activated by ROS [18,19], we tested whether
this kinase is also stimulated by pervanadate in SMCs, and
thus, may play a role in inhibiting MEK-1. Pervanadate acti-
vated p38MAPK in a dose-dependent fashion with kinase activ-
ity ¢rst detectable at 10 WM pervanadate. Higher doses of
pervanadate, 30 and 100 WM, further stimulated p38MAPK
up to 8-fold above basal levels (Fig. 2A, B). p38MAPK activity
reaches its maximum 10 min after the addition of pervanadate
(Fig. 2C); at that time, the loss of MEK-1 activity is observed
(Fig. 1C). Thus, the dose response and the kinetics of perva-
nadate-induced p38MAPK agree with the possibility that
p38MAPK blocks MEK-1 activation.
To examine the hypothesis that p38MAPK may block MEK-1,
we employed the speci¢c p38MAPK inhibitor SB203580
[20,21]. SMCs were preincubated with various concentrations
of SB203580 and stimulated for 30 min with 100 WM perva-
nadate. Besides MEK-1, we also determined the activity of
MAPKAPK-2, which is a downstream substrate for
p38MAPK, to monitor the e⁄cacy of the p38MAPK inhibitor.
Under these conditions, SB203580 (0.8^25 WM) caused
MEK-1 activation in a dose-dependent manner with a 6-fold
stimulation in the presence of 25 WM inhibitor (Fig. 3). This
suggested to us that the suppression of p38MAPK was su⁄cient
to allow MEK-1 activation by 100 WM pervanadate. As ex-
pected, in the absence of SB203580, pervanadate stimulated
MAPKAPK-2 activities. This stimulation was abolished by
SB203580 concentrations (0.8^2.5 WM) lower than those re-
quired to induce MEK-1 activation (Fig. 3). This di¡erence
may be explained by a role of p38MAPK isoforms, such as
SAPK3 and SAPK4 [2,22], which are less sensitive to
SB203580 and may also contribute to the inhibitory e¡ect
on MEK-1. However, we can not rule out that in addition
to blocking p38MAPK, SB203580 might have non-speci¢c ef-
fects at higher doses. In control experiments, where 25 WM
SB203580 were added to 10 WM pervanadate, the p38MAPK
inhibitor had no activatory e¡ect on MEK-1 (data not
shown).
3.3. p38MAPK does not signi¢cantly phosphorylate MEK-1
p38MAPK was immunoprecipitated from pervanadate-stimu-
lated cells and kinase activities were determined towards
ATF-2 and MEK-1 in the absence and presence of
SB203580. As positive control for the MEK-1 preparation,
we assayed Raf-1 following immunoprecipitation from
PDGF-BB-treated SMCs. Stimulation of p38MAPK resulted
in a 15-fold increase in ATF-2 phosphorylation but only in
a 1.5-fold increase in MEK-1 phosphorylation. Under identi-
cal assay conditions, stimulation of Raf-1 yielded a 20-fold
increase in MEK-1 phosphorylation (Fig. 4). As expected, in
the presence of SB203580, p38MAPK activity was abolished.
We estimated that p38MAPK incorporated less than 0.1 mol
phosphate/mol into MEK-1. Furthermore, immunoprecipi-
tated, PDGF-BB-activated MEK-1 was not inhibited by pre-
incubation with pervanadate-stimulated p38MAPK (data not
shown). From these data, we conclude that p38MAPK does
not exert its inhibitory e¡ect on MEK-1 by directly phospho-
rylating the kinase. As mentioned above, it is possible, how-
ever, that other p38MAPK isoforms such as SAPK3 and
SAPK4 are involved and may phosphorylate and inhibit
MEK-1.
3.4. Summary
We show that low concentrations of pervanadate result in a
sustained activation of MEK-1, whereas high concentrations
only transiently activate MEK-1. This di¡erence can be ex-
plained by an inhibitory e¡ect of pervanadate that is, at least
partially, mediated by a member of the p38MAPK family. This
inhibitory e¡ect on MEK-1 might be cell type speci¢c since it
has not been observed in HeLa cells [17]. In those studies,
however, MEK-2 was investigated rather than MEK-1. It is
therefore possible that only the MEK-1 isoform is sensitive to
pervanadate inhibition. In SMCs, we could not test this pos-
sibility, as MEK-2 activity is not detectable following perva-
nadate stimulation (not shown). It is an intriguing possibility
that the blockade of MEK-1 activation by p38MAPK is part of
the mechanisms by which DNA damaging agents cause
growth inhibition. Clearly, future work has to be directed
towards the elucidation of the molecular basis for p38MAPK-
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Fig. 3. E¡ect of the p38MAPK inhibitor SB203580 on MEK-1 and
MAPKAPK-2 activities in the presence of 100 WM pervanadate.
SMCs were preincubated for 1 h with 0.25% DMSO and various
concentrations of SB203580 as indicated. Cells were stimulated for
30 min with 100 WM pervanadate and extracted. MEK-1 activities
were determined with recombinant ERK-2 as substrate and MAP-
KAP kinase-2 was measured as described in Section 2.3. Data
(mean þ S.D. of independent experiments) are presented as percent
activity where the highest activities obtained are 100%. Solid bars:
MEK-1 (n = 3); hatched bars: MAPKAPK-2 (n = 2).
Fig. 4. p38MAPK does not signi¢cantly phosphorylate MEK-1.
p38MAPK and Raf-1 were immunoprecipitated from starved SMCs
and cells that were stimulated for 10 min with 100 WM pervanadate
and 10 ng/ml PDGF-BB, respectively. p38MAPK activities (black
bars) were measured with GST-ATF-2 and MEK-1 as substrates in
the absence and presence of 8 WM SB203580. As control, MEK-1
was used as substrate for Raf-1 (white bars). Data are presented as
percent phosphate incorporated, with GST-ATF-2 being 100%
(mean þ S.D., n = 3 except n = 2 for Raf assays and assays including
SB203580).
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mediated MEK-1 inhibition, as well as the identi¢cation of
the p38MAPK-dependent signaling element that is executing the
inhibitory e¡ect.
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